How the different molecular effects of the Maf1 knockout are partitioned in terms of energy expenditure and obesity resistance has yet to be determined, but our current results already establish MAF1 as a novel and unconventional therapeutic target for the treatment of obesity and related diseases. Here, MAF1 is linked to obesity due to melanocortin 4 receptor deficiency.